Detection of extraprostatic prostate cells utilizing reverse transcription-polymerase chain reaction

Seminars in Surgical Oncology

Volumn 18, Issue 1, 2000, Pages 17-28

  Su, Sai L ^a   Boynton, Alton L ^a   Holmes, Eric H ^a   Elgamal, Abdel Aziz A ^a   Murphy, Gerald P ^b  

^a Northwest Biotherapeutics Inc   (United States)

^b PACIFIC NORTHWEST RESEARCH INSTITUTE   (United States)

Author keywords

Bone marrow; Cultured tumor cells; False negative reactions; False positive reactions; Immunohistochemistry; Kallikrein; Lymph nodes; Messenger RNA; Needle biopsy; Neoadjuvant therapy; Neoplasm antigens; Neoplasm circulating cells; Neoplasm staging; Polymerase chain reaction; Predictive value of tests; Prostate specific antigen; Prostatectomy; Prostatic neoplasms; Reverse transcription polymerase chain reaction; Sensitivity and specificity; Surface antigens

Indexed keywords

ANDROGEN; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; TISSUE KALLIKREIN; TUMOR ANTIGEN; TUMOR MARKER;

BLOOD; BONE MARROW METASTASIS; CANCER ADJUVANT THERAPY; CANCER STAGING; CYSTOSCOPY; DIAGNOSTIC ACCURACY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; METASTASIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW;

ANTIGENS, SURFACE; BIOPSY; CARBOXYPEPTIDASES; DIAGNOSIS, DIFFERENTIAL; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; LYMPH NODES; MALE; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 0033986145     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2388(200001/02)18:1<17::AID-SSU4>3.0.CO;2-7     Document Type: Review

References (111)

1. Landis SH, Murray T, Bolden S, Wingo PA: Cancer statistics, 1999. CA Cancer J Clin 1999;49:8-31.
2. Epstein JI, Pizov G, Walsh PC: Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 1993;71:3582-3593.
3. Fowler JE Jr, Whitmore WF Jr: The incidence and extent of pelvic lymph node metastases in apparently localized prostatic cancer. Cancer 1981;47:2941-2945.
4. Kleer E, Oesterling JE: PSA and staging of localized prostate cancer. Urol Clin North Am 1993;20:695-704.
5. Mukamel E, Hanna J, deKernion JB: Pitfalls in preoperative staging in prostate cancer. Urology 1987;30:318-321.
6. Partin AW, Carter HB, Chan DW, et al: Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 1990;143:747-752.
7. Rosen MA, Goldstone L, Lapin S, et al: Frequency and location of extracapsular extension and positive surgical margins in radical prostatectomy specimens. J Urol 1992;148(2 Pt 1): 331-337.
8. Lu-Yao GL, Greenberg ER: Changes in prostate cancer incidence and treatment in USA. Lancet 1994;343(8892):251-254.
9. Schellhammer PF: Radical prostatectomy. Patterns of local failure and survival in 67 patients. Urology 1988;31:191-197.
10. Lerner SP, Seale-Hawkins C, Carlton CE Jr, Scardino PT: The risk of dying of prostate cancer in patients with clinically localized disease. J Urol 1991;146:1040-1045.
11. Ozen M, Navone NM, Multani AS, et al: Structural alterations of chromosome 5 in twelve human prostate cancer cell lines. Cancer Genet Cytogenet 1998;106:105-109.
12. Dal Cin P, Van den Berghe H: Chromosome abnomalities in Adenocarcinoma of the Prostate. In: Petrovich Z, Baert L, Brady LW (eds): "Carcinoma of the prostate: innovations in management." New York: Springer; 1996. p. 51-52.
13. Brothman AR, Maxwell TM, Cui J, et al: Chromosomal clues to the development of prostate tumors [Review]. Prostate 1999;38: 303-312.
14. Poste G, Fidler IJ: The pathogenesis of cancer metastasis [Review]. Nature 1980;283(5743):139-146.
15. Fidler IJ: Metastasis: quantitative analysis of distribution and fate of tumor embolilabeled with 125 I-5-iodo-2′-deoxyuridine. J Natl Cancer Inst 1970;45:773-782.
16. Fidler IJ, Kripke ML: Metastasis results from preexisting variant cells within a malignant tumor. Science 1977;197(4306):893-895.
17. Hamdy FC, Lawry J, Anderson JB, et al: Circulating prostate specific antigen-positive cells correlate with metastatic prostate cancer. Br J Urol 1992;69:392-396.
18. Vessella RL, Riley DE, Blouke KA, et al: A sensitive method for detection of a prostate tumor cell marker using the polymerase chain reaction [Abstract]. J Urol 1992;147(Suppl):441A.
19. Moreno JG, Croce CM, Fischer R, et al: Detection of hematogenous micrometastasis in patients with prostate cancer. Cancer Res 1992;52:6110-6112.
20. Berteau P, Dumas F, Gala JL, et al: Influence of blood storage and sample processing on molecular detection of circulating prostate cells in cancer. Clin Chem 1998;44:677-679.
21. Vessella RL, Corey E: Detection of prostate-cancer cells in blood and bone marrow by RT-PCR. In: Hanausek M, Walaszek Z (eds): "Methods in molecular medicine." Totowa, New Jersey: Humana; 1997. p. 357-371.
22. Corey E, Corey MJ: Detection of disseminated prostate cells by reverse transcription-polymerase chain reaction (RT-PCR): technical and clinical aspects [Review]. Int J Cancer 1998;77: 655-673.
23. Wang MC, Papsidero LD, Kuriyama M, et al: Prostate antigen: a new potential marker for prostatic cancer. Prostate 1981;2:89-96.
24. Epstein JI: PSA and PAP as immunohistochemical markers in prostate cancer [Review]. Urol Clin North Am 1993;20:757-770.
25. Nadji M, Tabei SZ, Castro A, et al: Prostatic-specific antigen: an immunohistologic marker for prostatic neoplasms. Cancer 1981;48:1229-1232.
26. Papsidero LD, Kuriyama M, Wang MC, et al: Prostate antigen: a marker for human prostate epithelial cells. J Natl Cancer Inst 1981;66:37-42.
27. Ford TF, Butcher DN, Masters JR, Parkinson MC: Immunocytochemical localisation of prostate-specific antigen: specificity and application to clinical practice. Br J Urol 1985;57:50-55.
28. Frazier HA, Humphrey PA, Burchette JL, Paulson DF: Immunoreactive prostatic specific antigen in male periurethral glands. J Urol 1992;147:246-248.
29. Elgamal AA, Ectors NL, Sunardhi-Widyaputra S, et al: Detection of prostate specific antigen in pancreas and salivary glands: a potential impact on prostate cancer overestimation. J Urol 1996;156(2 Pt 1):464-468.
30. van Krieken JH: Prostate marker immunoreactivity in salivary gland neoplasms. A rare pitfall in immunohistochemistry. Am J Surg Pathol 1993;17:410-414.
31. Wood DP Jr, Banks ER, Humphreys S, Rangnekar VM: Sensitivity of immunohistochemistry and polymerase chain reaction in detecting prostate cancer cells in bone marrow. J Histochem Cytochem 1994;42:505-511.
32. O'Hara SM, Veltri RW, Skirpstunas P: Basal PSA mRNA level detected by quantitative reverse transcriptase polymerase chain reaction (Q-RT-PCR-PSA) in blood from subjects without prostate cancer [Review]. J Urol 1996;155(Suppl):430A.
33. Corey E, Arfman EW, Liu AY, Vessella RL: Improved reverse transcriptase-polymerase chain reaction protocol with exogenous internal competitive control for prostate-specific antigen mRNA in blood and bone marrow. Clin Chem 1997;43:443-452.
34. Gala JL, Heusterspreute M, Loric S, et al: Expression of prostate-specific antigen and prostate-specific membrane antigen transcripts in blood cells: implications for the detection of hematogenous prostate cells and standardization. Clin Chem 1998;44:472-481.
35. Sokoloff MH, Tso CL, Kaboo R, et al: Quantitative polymerase chain reaction does not improve preoperative prostate cancer staging: a clinicopathological molecular analysis of 121 patients. J Urol 1996;156:1560-1566.
36. Horoszewicz JS, Kawinski E, Murphy GP: Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 1987;7:927-935.
37. Troyer JK, Beckett ML, Wright GL Jr: Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer 1995;62:552-558.
38. Silver DA, Pellicer I, Fair WR, et al: Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997;3:81-85.
39. Bostwick DG, Pacelli A, Blute M, et al: Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 1998;82:2256-2261.
40. Sweat SD, Pacelli A, Murphy GP, Bostwick DG: Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases [Review]. Urology 1998; 52:637-640.
41. Israeli RS, Powell CT, Corr JG, et al: Expression of the prostate-specific membrane antigen. Cancer Res 1994;54:1807-1811.
42. Kawakami M, Nakayama J: Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Cancer Res 1997;57:2321-2324.
43. Wright GL J, Grob BM, Haley C, et al: Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1996;48:326-334.
44. Murphy GP, Elgamal AA, Su SL, et al: Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen [Review]. Cancer 1998;83:2259-2269.
45. Fair WR, Israeli RS, Heston WD: Prostate-specific membrane antigen [Review]. Prostate 1997;32:140-148.
46. Gregorakis AK, Holmes EH, Murphy GP: Prostate-specific membrane antigen: current and future utility [Review]. Semin Urol Oncol 1998;16:2-12.
47. Schedlich LJ, Bennetts BH, Morris BJ: Primary structure of a human glandular kallikrein gene. DNA 1987;6:429-437.
48. Daher R, Beaini M: Prostate-specific antigen and new related markers for prostate cancer [Review]. Clin Chem Lab Med 1998; 36:671-681.
49. Saedi MS, Hill TM, Kuus-Reichel K, et al: The precursor form of the human kallikrein 2, a kallikrein homologous to prostate-specific antigen, is present in human sera and is increased in prostate cancer and benign prostatic hyperplasia. Clin Chem 1998;44:2115-2119.
50. Rittenhouse HG, Finlay JA, Mikolajczyk SD, Partin AW: Human kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate [Review]. Crit Rev Clin Lab Sci 1998;35:275-368.
51. Hsieh ML, Charlesworth MC, Goodmanson M, et al: Expression of human prostate-specific glandular kallikrein protein (hK2) in the breast cancer cell line T47-D. Cancer Res 1997;57:2651-2656.
52. Henke W, Jung M, Jung K, et al: Increased analytical sensitivity of RT-PCR of PSA mRNA decreases diagnostic specificity of detection of prostatic cells in blood. Int J Cancer 1997;70:52-56.
53. Thiounn N, Saporta F, Flam TA, et al: Positive prostate-specific antigen circulating cells detected by reverse transcriptase-polymerase chain reaction does not imply the presence of prostatic micrometastases. Urology 1997;50:245-250.
54. Lintula S, Stenman UH: The expression of prostate-specific membrane antigen in peripheral blood leukocytes. J Urol 1997;157: 1969-1972.
55. Zippelius A, Kufer P, Honold G, et al: Limitations of reverse-transcriptase polymerase chain reaction analyses for detection of micrometastatic epithelial cancer cells in bone marrow. J Clin Oncol 1997;15:2701-2708.
56. Corey E, Arfman EW, Oswin MM, et al: Detection of circulating prostate cells by reverse transcriptase-polymerase chain reaction of human glandular kallikrein (hK2) and prostate-specific antigen (PSA) messages. Urology 1997;50:184-188.
57. Kawakami M, Okaneya T, Furihata K, et al: Detection of prostate cancer cells circulating in peripheral blood by reverse transcription-PCR for hKLK2. Cancer Res 1997;57:4167-4170.
58. Nguyen C, Dickason R, Song W, et al: RT-PCR for hK2 mRNA: a new assay for detecting circulating prostate cells [Abstract]. J Urol 1997;157(Suppl):A436.
59. Riesenberg R, Oberneder R, Kriegmair M, et al: Immunocytochemical double staining of cytokeratin and prostate specific antigen in individual prostatic tumour cells. Histochemistry 1993;99:61-66.
60. Mueller P, Carroll P, Bowers E, et al: Low frequency epithelial cells in bone marrow aspirates from prostate carcinoma patients are cytogenetically aberrant. Cancer 1998;83:538-546.
61. Jobsis AC, De Vries DP, Anholt RR, Sanders GT: Demonstration of the prostatic origin of metastases: an immunohistochemical method for formalin-fixed embedded tissue. Cancer 1978;41: 1788-1793.
62. Shevchuk MM, Romas NA, Ng PY, et al: Acid phosphatase localization in prostatic carcinoma. A comparison of monoclonal antibody to heteroantisera. Cancer 1983;52:1642-1626.
63. Lundgren R, Mandahl N, Heim S, et al: Cytogenetic analysis of 57 primary prostatic adenocarcinoma. Genes Chromosomes Cancer 1992;4:16-24.
64. Alers JC, Krijtenburg PJ, Vissers KJ, et al: Interphase cytogenetics of prostatic adenocarcinoma and precursor lesions: analysis of 25 radical prostatectomies and 17 adjacent prostatic intraepithelial neoplasias. Genes Chromosomes Cancer 1995;12:241-250.
65. Alers JC, Krijtenburg PJ, Rosenberg C, et al: Interphase cytogenetics of prostatic tumor progression: specific chromosomal abnormalities are involved in metastasis to the bone. Lab Invest 1997;77:437-448.
66. Alers JC, Krijtenburg PJ, Hop WC, et al: Longitudinal evaluation of cytogenetic aberrations in prostatic cancer: tumours that recur in time display an intermediate genetic status between non-persistent and metastatic tumours. J Pathol 1998;185:273-283.
67. Wullich B, Breitkreuz T, Zwergel T, et al: Cytogenetic evidence of intratumoral focal heterogeneity in prostatic carcinomas. Urol Int 1992;48:372-377.
68. Azar GM, DiPillo F, Gogineni SK, et al: Highly complex chromosomal aberrations in bone marrow of a patient with metastatic prostate neoplasm. Cancer Genet Cytogenet 1997;99:116-120.
69. Ohnuki Y, Marnell MM, Babcock MS, et al: Chromosomal analysis of human prostatic adenocarcinoma cell lines. Cancer Res 1980;40:524-534.
70. Nupponen NN, Kakkola L, Koivisto P, Visakorpi T: Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am J Pathol 1998;153:141-148.
71. Grasso YZ, Gupta MK, Levin HS, et al: Combined nested RT-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in prostate cancer patients: correlation with pathological stage. Cancer Res 1998;58:1456-1459.
72. Zhang Y, Zippe CD, Van Lente F, et al: Combined nested reverse transcription-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in detecting circulating prostatic Cells. Clin Cancer Res 1997;3:1215-1220.
73. Katz AE, Olsson CA, Raffo AJ, et al: Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay. Urology 1994;43:765-775.
74. Cama C, Olsson CA, Raffo AJ, et al: Molecular staging of prostate cancer. II. A comparison of the application of an enhanced reverse transcriptase polymerase chain reaction assay for prostate specific antigen versus prostate specific membrane antigen. J Urol 1995;153:1373-1378.
75. Katz AE, De Vries GM, Olsson CA, et al: Molecular staging of genitourinary malignancies [Review]. Urology 1996;47:948-958.
76. Olsson CA, de Vries GM, Raffo AJ, et al: Preoperative reverse transcriptase polymerase chain reaction for prostate specific antigen predicts treatment failure following radical prostatectomy. J Urol 1996;155:1557-1562.
77. Olsson CA, De Vries GM, Benson MC, et al: The use of RT-PCR for prostate-specific antigen assay to predict potential surgical failures before radical prostatectomy: molecular staging of prostate cancer. Br J Urol 1996;77:411-417.
78. Ennis RD, Katz AE, De Vries GM, et al: Detection of circulating prostate carcinoma cells via an enhanced reverse transcriptase-polymerase chain reaction assay in patients with early stage prostate carcinoma. Independence from other pretreatment characteristics. Cancer 1997;79:2402-2408.
79. Nejat RJ, Katz AE, Benson MC, et al: Enhanced RT-PCR for PSA combined with serum PSA predicts pathologic stage and outcome in 3000 radical prostatectomy patients [Abstract]. J Urol 1998;159:291A.
80. Okegawa T, Yoshioka J, Morita R, et al: Molecular staging of prostate cancer: comparison of nested reverse transcription polymerase chain reaction assay using prostate specific antigen versus prostate specific membrane antigen as primer. Int J Urol 1998; 5:349-356.
81. Ghossein RA, Scher HI, Gerald WL, et al: Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implications. J Clin Oncol 1995;13:1195-1200.
82. Katz AE, de Vries GM, Benson MC, et al: The role of the reverse-transcriptase polymerase chain reaction assay for prostate-specific antigen in the selection of patients for radical prostatectomy [Review]. Urol Clin North Am 1996;23:541-549.
83. Ghossein RA, Rosai J, Scher HI, et al: Prognostic significance of detection of prostate-specific antigen transcripts in the peripheral blood of patients with metastatic androgen-independent prostatic carcinoma. Urology 1997;50:100-105.
84. Ellis WJ, Vessella RL, Corey E, et al: The value of a reverse transcriptase polymerase chain reaction assay in preoperative staging and followup of patients with prostate cancer. J Urol 1998;159: 1134-1138.
85. Wood DP Jr, Banks ER, Humphreys S, et al: Identification of bone marrow micrometastases in patients with prostate cancer. Cancer 1994;74:2533-2540.
86. Wood DP Jr, Banerjee M: Presence of circulating prostate cells in the bone marrow of patients undergoing radical prostatectomy is predictive of disease-free survival. J Clin Oncol 1997;15:3451-3457.
87. Deguchi T, Yang M, Ehara H, et al: Detection of micrometastatic prostate cancer cells in the bone marrow of patients with prostate cancer. Br J Cancer 1997;75:634-638.
88. Melchior SW, Corey E, Ellis WJ, et al: Early tumor cell dissemination in patients with clinically localized carcinoma of the prostate. Clin Cancer Res 1997;3:249-256.
89. Deguchi T, Doi T, Ehara H, et al: Detection of micrometastatic prostate cancer cells in lymph nodes by reverse transcriptase-polymerase chain reaction. Cancer Res 1993;53:5350-5354.
90. Edelstein RA, Zietman AL, de las Morenas A, et al: Implications of prostate micrometastases in pelvic lymph nodes: an archival tissue study. Urology 1996;47:370-375.
91. Ferrari AC, Stone NN, Eyler JN, et al: Prospective analysis of prostate-specific markers in pelvic lymph nodes of patients with high-risk prostate cancer. J Natl Cancer Inst 1997;89:1498-1504.
92. Hoshi S, Kobayashi S, Takahashi T, et al: Enzyme-linked immunosorbent assay detection of prostate-specific antigen messenger ribonucleic acid in prostate cancer. Urology 1999;53: 228-235.
93. Fowler JE Jr, Brooks J, Pandey P, Seaver LE: Variable histology of anastomotic biopsies with detectable prostate specific antigen after radical prostatectomy. J Urol 1995;153(3 Pt 2):1011-1014.
94. Oesterling JE, Rice DC, Glenski WJ, Bergstralh EJ: Effect of cystoscopy, prostate biopsy, and transurethral resection of prostate on serum prostate-specific antigen concentration. Urology 1993;42-276-282.
95. Eschwege P, Dumas F, Blanchet P, et al: Haematogenous dissemination of prostatic epithelial cells during radical prostatectomy. Lancet 1995;346(8989):1528-1530.
96. Su SL, Heston WD, Perrotti M, et al: Evaluating neoadjuvant therapy effectiveness on systemic disease: use of a prostatic-specific membrane reverse transcription polymerase chain reaction [published erratum appears in Urology 1998;51:352] [Review]. Urology 1997;49(3A Suppl):95-101.
97. Moreno JG, Shenot PJ, Shupp-Byrne D, Gomella LG: Analysis of tumor spillage during radical prostatectomy using RT-PCR of prostate specific antigen. Tech Urol 1996;2:54-57.
98. Planz B, Szyska P, Valdor M, et al: Detection of circulating prostatic cells during radical prostatectomy. Urol Res 1997;25:385-389.
99. Cama C, Olsson CA, Buttyan R, et al: Molecular staging of prostate cancer. III. Effects of cystoscopy and needle biopsy on the enhanced reverse transcriptase polymerase chain reaction assay. J Urol 1997;157:1748-1751.
100. rd, et al: Detection and clearance of prostate cells subsequent to ultrasound-guided needle biopsy as determined by multiplex nested reverse transcription polymerase chain reaction assay. Urology 1998;52:261-267.
101. de Cremoux P, Ravery V, Podgorniak MP, et al: Value of the preoperative detection of prostate-specific-antigen-positive circulating cells by nested RT-PCR in patients submitted to radical prostatectomy. Eur Urol 1997;32:69-74.
102. Goldman HB, Israeli RS, Lu Y, et al: Can prostate-specific antigen reverse transcriptase-polymerase chain reaction be used as a prospective test to diagnose prostate cancer? World J Urol 1997;15:257-261.
103. Ignatoff JM, Oefelein MG, Watkin W, et al: Prostate specific antigen reverse transcriptase-polymerase chain reaction assay in preoperative staging of prostate cancer. J Urol 1997;158:1870-1875.
104. Israeli RS, Miller WH Jr, Su SL, et al: Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays. Cancer Res 1994;54:6306-6310.
105. Jaakola S, Vornanen T, Leinonen J, et al: Detection of prostatic cells in peripheral blood: correlation with serum concentrations of prostate-specific antigen [Abstract]. Clin Chem 1995;41:182-186.
106. Loric S, Dumas F, Eschwege P, et al: Enhanced detection of hematogenous circulating prostatic cells in patients with prostate adenocarcinoma by using nested reverse transcription polymerase chain reaction assay based on prostate-specific membrane antigen. Clin Chem 1995;41(12 Pt 1):1698-1704.
107. rd, Wojcik L, et al: Application of immunomagnetic beads in combination with RT-PCR for the detection of circulating prostate cancer cells. J Clin Lab Anal 1997;11:346-350.
108. Mangold KA, Liang Y, Johnson M, et al: Enhanced RT-PCR assay for mRNA expression of prostate specific antigen and prostate specific membrane antigen in peripheral blood: is it reliable? Mol Urol 1998;2:29-34.
109. Seiden MV, Kantoff PW, Krithivas K, et al: Detection of circulating tumor cells in men with localized prostate cancer. J Clin Oncol 1994;12:2634-2639.
110. Noguchi M, Miyajima J, Itoh K, Noda S: Detection of circulating tumor cells in patients with prostate cancer using prostate specific membrane-derived primers in the polymerase chain reaction. Int J Urol 1997;4:374-379.
111. Wood DP Jr, Beaman A, Banerjee M, et al: Effect of neoadjuvant androgen deprivation on circulating prostate cells in the bone marrow of men undergoing radical prostatectomy. Clin Cancer Res 1998;4:2119-2123.